Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/toxicology.4.014
Commentary on: Catalytic antioxidants to treat amyotrophic lateral sclerosis
John P. Crow1,*
- 1Professor Emeritus of Anesthesiology/Biochemistry/Pharmacology/Toxicology, University of Arkansas for Medical Sciences, College of Medicine, 4301 W. Markham Slot 638, Little Rock, AR 72205, USA
Corresponding Author
John P. Crow, CrowJohnP@uams.edu
Received Date: January 13, 2022
Accepted Date: February 11, 2022
Citation:
Crow JP. Commentary on: Catalytic antioxidants to treat amyotrophic lateral sclerosis. Arch Clin Toxicol. 2022;4(1):1-4.
Copyright: © 2022 Crow JP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Commentary on: Catalytic antioxidants to treat amyotrophic lateral sclerosis
A 2006 publication entitled ‘Catalytic Antioxidants to Treat Amyotrophic Lateral Sclerosis’ summarized the therapeutic effects of metalloporphyrins (MPs) and metallotexaphyrins (MTs) in the G93A superoxide dismutase (SOD1) mouse model of amyotrophic lateral sclerosis (ALS)